Lexicon Pharmaceuticals, Inc (LXRX)

Check out top investors' recommendation for LXRX
Last closing price (N/A)
(0.00%) ? 
Last closing price is the stock price upon last market close (date specified in parenthesis).
Return to date (1m/3m/6m/12m):
N/A ? 
Return to date is the stock return for the specified period of time.
Consensus price target (1m/3m/6m/12m):
26.67
 ? 
Consensus price target is the average analyst price target for a specified period of time.
Buy/Sell Mix (1m/3m/6m/12m):
67%/33%
 ? 
Buy/sell mix the percentage mix between Buy and Sell recommendations for a given company or a research firm. Hold recommendations are excluded.
Description:
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery and development of treatments for human disease. Its portfolio of orally-delivered small molecule compounds in clinical development include LX4211 that has completed two Phase II clinical trials for the treatment of type 1 and type 2 diabetes; LX1032, which is in Phase III clinical trials for the treatment of carcinoid syndrome and ulcerative colitis; and LX1033 that is in Phase II clinical trials for the treatment of irritable bowel syndrome. The company is also developing LX2931 that has completed Phase II clinical trials for the treatment of rheumatoid arthritis; and LX7101, which is in Phase I clinical trials for the treatment of glaucoma. It has drug discovery and development collaborations with Bristol-Myers Squibb Company; Genentech, Inc.; Schering-Plough/Organon; and Takeda Pharmaceutical Company Limited. Lexicon Pharmaceuticals, Inc. was founded in 1995 and is headquartered in The Woodlands, Texas.
Sector:
Industry:
Analyst
An analyst is a professional research analyst or an Investor Wand user who issued a recommendation for a given company.
Research Firm
A Research Firm is a company that researches and rates stocks and publishes recommendations.
Signal
Signal is a recommendation issued by an analyst. Investor Wand considers two types of recommendations: BUY and SELL.
Signal Date
A signal date is a date when a BUY or SELL recommendation was issued for given security.
Initial Price
Initial Price is the first closing price for a specified company upon recommendation release. If the recommendation is issued in after-market hours, the Initial Price is the next day’s closing price (for a given symbol). In case of dividend distributions and stock splits, Initial Price is adjusted.
Price Target
A Price Target is an analyst’s projection of a company’s stock price by the end of the recommendation period. It represents the price at which the analyst would exit his or her existing position.
Closing Date
Closing Date is the expiration date of a recommendation. The validity timeframe of a professional analyst’s recommendation is 12 months. Investor Wand analysts can set their recommendation timeframe to one, three, six, or 12 months.
Return
The return on a single open recommendation is calculated as the maximum of the current return (based on the latest closing price) and the target price return, if the symbol reached the target. The return on a single closed recommendation is calculated as the maximum of the return on the closing date (at the end of recommendation timeframe) and the target price return, if the stock hit the target price. The return is adjusted for one-time events (e.g., stock splits).
Kevin Kedra Gabelli & Company Sell   Mar 14, '19     6.00  Mar 14, '20  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Mar 04, '19     38.00  Mar 04, '20  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Jan 22, '19     36.00  Jan 22, '20  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Jul 31, '18     44.00  Jul 31, '19  N/A 
Stephen Willey Stifel Nicolaus & Company, Inc. Buy   Jul 30, '18     23.00  Jul 30, '19  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   May 22, '18     42.00  May 22, '19  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Mar 12, '18     38.00  Mar 12, '19  N/A 
Jessica Fye JPMorgan Sell   Feb 14, '18     10.00  Feb 14, '19  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Nov 30, '17     38.00  Nov 30, '18  N/A 
Alan Carr Needham & Company Buy   Nov 08, '17     21.00  Nov 08, '18  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Oct 05, '17     38.00  Oct 05, '18  N/A 
Stephen Willey Stifel Nicolaus & Company, Inc. Buy   Sep 08, '17     27.00  Sep 08, '18  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Aug 07, '17       Aug 07, '18  N/A 
Alan Carr Needham & Company Buy   Aug 01, '17       Aug 01, '18  N/A 
Alan Carr Needham & Company Buy   Jan 27, '17     21.00  Jan 27, '18  N/A 
Gerardo Torculas Unaffiliated Buy   Jan 12, '17   14.75  16.00  Feb 12, '17  3.46% 
Alan Carr Needham & Company Buy   Nov 01, '16     21.00  Nov 01, '17  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Sep 20, '16     33.00  Sep 20, '17  N/A 
Liana Moussatos Wedbush Securities Inc. Buy   Aug 05, '16     31.00  Aug 05, '17  N/A 
Stephen Willey Stifel Nicolaus & Company, Inc. Buy   Aug 05, '16     26.00  Aug 05, '17  N/A 
< previous12